anemia in patients with type 2 diabetic kidney disease
Conditions
Interventions
trial group:Quercetin capsules 500mg bid
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) 18=age=80, type 2 diabetes, HbA1c = 9%; 2) The clinical diagnosis was DKD, 30 mg/g =UACR and/or eGFR=60 ml/min/1.73m2 and course of disease = half a year; 3) The diagnostic criteria for anemia were met: hemoglobin (HGB) <130g / L for men and <120g / L for women;
Exclusion criteria
Exclusion criteria: 1) Iron agent, erythropoiesis stimulator (ESA), hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors, or SGLT 2 inhibitors within 5 weeks before enrollment; 2) Chronic kidney disease of other causes: such as nephrotic syndrome, autosomal dominant or autosomal-negative polycystic kidney disease; kidney disease requiring immunosuppressive agent treatment, patients with a history of dialysis or kidney transplantation; 3) Other diseases known to cause anemia, such as myelodysplastic syndrome, multiple myeloma, hereditary blood diseases, etc.; 4) Chronic inflammatory diseases that can affect erythropoiesis: such as systemic lupus erythematosus, rheumatoid arthritis, hyperthyroidism, celiac disease, etc.; 5) Known severe liver disease: AST / ALT exceeds 3 times the upper limit of normal or total bilirubin exceeds 2 times the upper limit of normal; 6) Grade NYHA 3 or Grade 4 heart failure, acute cardiovascular events, stroke, epilepsy, or thromboembolic events within 1 year; 7) Patients with uncontrolled resistant hypertension (SBP=180mmHg and / or DBP=100mmHg), body mass index (BMI) =30 kg/m2, or history of malignancy (except for cancer that has been cured or relieved for> 5 years); 8) A pregnancy plan during pregnancy and lactation or during the study; 9) Allergy or intolerance to flavonoids; 10) Any medical condition that the investigator considers poses a safety risk, confounding efficacy or safety assessments, or interfering with study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood routine examination;Erythropoietin (EPO);UACR;reticulocyte;HbA1c; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver and kidney function;Blood lipid;Blood electrolyte;urinalysis; | — |
Countries
China
Contacts
Public ContactGuijun Qin
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed